公开(公告)号：US12128018B2

公开(公告)日：2024-10-29

申请号：US16246320

申请日：2019-01-11

Applicant: KDAc Therapeutics, Inc.

Inventor： Edward Holson ,  Mariana Nacht

IPC: A01N43/00 ,  A01N43/46 ,  A61K31/167 ,  A61K31/403 ,  A61K31/415 ,  A61K31/55 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28 ,  A61K39/00

CPC classification number: A61K31/167 ,  A61K31/403 ,  A61K31/415 ,  A61K39/3955 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2818 ,  A61K2039/545 ,  C07K2317/73 ,  A61K31/167 ,  A61K2300/00 ,  A61K31/403 ,  A61K2300/00 ,  A61K31/415 ,  A61K2300/00 ,  A61K39/3955 ,  A61K2300/00

Abstract: Aspects of the disclosure relate to compositions, kits, and methods for the treatment of cancer that utilize a selective histone deacetylase 3 (HDAC3) inhibitor. In some aspects, the compositions, kits, and methods relate to use of a selective HDAC3 inhibitor in combination with an immunotherapy agent (e.g., an immune checkpoint inhibitor).

公开(公告)号：US20210177781A9

公开(公告)日：2021-06-17

申请号：US16246320

申请日：2019-01-11

Applicant: KDAc Therapeutics, Inc.

Inventor： Edward Holson ,  Mariana Nacht

IPC: A61K31/167 ,  C07K16/28 ,  A61P35/00

Abstract: Aspects of the disclosure relate to compositions, kits, and methods for the treatment of cancer that utilize a selective histonc deacetylase 3 (HDAC3) inhibitor. In some aspects, the compositions, kits, and methods relate to use of a selective HDAC3 inhibitor in combination with an immunotherapy agent (e.g., an immune checkpoint inhibitor).

公开(公告)号：US20190216754A1

公开(公告)日：2019-07-18

申请号：US16246320

申请日：2019-01-11

Applicant: KDAc Therapeutics, Inc.

Inventor： Edward Holson ,  Mariana Nacht

IPC: A61K31/167 ,  C07K16/28 ,  A61P35/00

CPC classification number: A61K31/167 ,  A61K31/403 ,  A61K31/415 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/545 ,  A61P35/00 ,  C07K16/2818 ,  C07K2317/73 ,  A61K2300/00

Abstract: Aspects of the disclosure relate to compositions, kits, and methods for the treatment of cancer that utilize a selective histonc deacetylase 3 (HDAC3) inhibitor. In some aspects, the compositions, kits, and methods relate to use of a selective HDAC3 inhibitor in combination with an immunotherapy agent (e.g., an immune checkpoint inhibitor).